Mandate

Vinge advises owner in connection with sale of Kung Markatta

May 06, 2013

Vinge has advised Ekomodern F, W & E AB in connection with the sale of Kung Markatta AB to Priveq Investment Fund IV. The company’s current indirect owners, i.e. Peter Enberg, Stefan Wilhelmson and CEO Anders Dahlin, will retain significant shareholdings through a new holding company formed in conjunction with the acquisition.

Kung Markatta is a market leader in Sweden within the distribution and marketing of ecological and natural products. The company, which was established in Örebro in 1983, has expanded significantly since it was acquired in 2004 by Peter Enberg and his partners. In addition to its own well-renowned range of approximately 150 ecological products under the Kung Markatta trade mark, the company also markets a large portfolio of other brands such as, among others, Alpro, Rice Dream, Yogi Tea, and Green & Black’s.  The company’s turnover in 2012 was approximately SEK 200 million and it currently employs 30 people.

Vinge’s team consisted of partner Daniel Rosvall together with, among others, associates Kristian Ford, Markus Larsson and Maria Dahlin.     

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024